Advanced visualization firm Viatronix has received U.S. Food and Drug Administration (FDA) 510(k) approval for its V3D-Cardiac module.
V3D-Cardiac combines left ventricle and coronary analysis functions into a single module, according to the Stony Brook, NY-based firm.
Related Reading
Visage, Viatronix ink marketing deal, November 25, 2008
Road to RSNA, CAD, Viatronix, November 1, 2007
Viatronix joins forces with Canadian integrator, August 28, 2007
Viatronix, Medicsight net CE Mark, June 13, 2007
Viatronix completes Massachusetts installations, March 1, 2007
Copyright © 2008 AuntMinnie.com